Syndax Pharmaceuticals Inc
SNDXHealthcare|Biotechnology|USA
$23.62
-1.23 (-4.95%)
Tangible Book
$0.47
Clinical Trials (51)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07211958 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Acute Myeloid Leukemias | P3 | Recruiting | 468 | RCT, Double-blind | Revumenib, Placebo, Intensive Chemotherapy Regimen |
| NCT05360160 A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Acute Myeloid Leukemia | P1P2 | Recruiting | 43 | Open-label | SNDX-5613, Venetoclax, ASTX727 |
| NCT03501381 High Dose IL 2 and Entinostat in RCC | Renal Cell Carcinoma | P2 | Active | 46 | RCT, Open-label | Entinostat, Interleukin-2 |
| NCT04710576 A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Chronic Graft-versus-host-disease | P2 | Recruiting | 296 | RCT, Open-label | Axatilimab |
| NCT06132256 MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P2 | Active | 145 | RCT, Double-blind | Axatilimab |
| NCT06229912 A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | Leukemia, HOX Gene | P2 | Recruiting | 40 | Open-label | Revumenib |
| NCT03978624 Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | Bladder Cancer | P2 | Active | 20 | RCT, Open-label | Pembrolizumab, Entinostat |
| NCT04065399 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P1P2 | Recruiting | 447 | Open-label | revumenib, cobicistat |
| NCT06284486 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | Acute Myeloid Leukemia | P1P2 | Recruiting | 8 | Open-label | Venetoclax, Revumenib |
| NCT03179930 Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | Lymphoma, Relapsed | P2 | Active | 47 | Open-label | Entinostat, Pembrolizumab |
| NCT06226571 A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Acute Myeloid Leukemias | P1 | Active | 76 | Open-label | SNDX-5613, Chemotherapy Regimen, HiDAC |
| NCT06177067 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | P1 | Recruiting | 24 | Open-label | Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate |
| NCT06313437 Revumenib in Combination With 7+3 + Midostaurin in AML | Acute Myeloid Leukemia, AML, Adult | P1 | Recruiting | 22 | Open-label | Revumenib, Midostaurin, Cytarabine, Daunorubicin |
| NCT03024437 Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | Metastatic Cancer, Renal Cancer | P1P2 | Terminated | 31 | Open-label | Atezolizumab, Bevacizumab, Entinostat |
| NCT00828854 Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | ER+ Breast Cancer | P2 | Completed | 27 | Open-label | Entinostat, Aromatase Inhibitor (AI) Therapy |
| NCT02708680 Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Breast Cancer | P1P2 | Completed | 89 | RCT, Double-blind | Entinostat, Atezolizumab, Placebo |
| NCT01234532 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery | Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | P2 | Terminated | 5 | Open-label | entinostat, anastrozole |
| NCT00602030 Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung | P1P2 | Completed | 141 | RCT, Double-blind | Entinostat, Placebo, Erlotinib |
| NCT05731947 Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Colorectal Cancer, Solid Tumors | P1P2 | Terminated | 41 | Open-label | Revumenib, Chemotherapy |
| NCT02697630 Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye | Metastatic Uveal Melanoma | P2 | Completed | 29 | Open-label | Pembrolizumab, Entinostat |
| NCT02115594 Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | Breast Cancer | P2 | Withdrawn | — | RCT, Double-blind | Fulvestrant, Entinostat, Placebo |
| NCT03250273 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Metastatic Cholangiocarcinoma, Cholangiocarcinoma | P2 | Completed | 44 | Open-label | Entinostat, Nivolumab, Entinostat, Nivolumab |
| NCT03765229 An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | Melanoma | P2 | Completed | 11 | Open-label | Entinostat, Pembrolizumab |
| NCT03604692 A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Chronic Graft-versus-host-disease | P1P2 | Completed | 41 | Open-label | axatilimab |
| NCT02915523 Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | Epithelial Ovarian Cancer, Peritoneal Cancer | P1P2 | Completed | 140 | RCT, Double-blind | entinostat, avelumab, Placebo |
| NCT00750698 A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | Non Small Cell Lung Cancer | P2 | Terminated | 8 | Open-label | Entinostat, Erlotinib |
| NCT02437136 Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | Non-Small Cell Lung Cancer, Melanoma | P1P2 | Completed | 191 | Open-label | entinostat, pembrolizumab |
| NCT01928576 Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | Non-Small Cell Lung Cancer, Epigenetic Therapy | P2 | Completed | 143 | RCT, Open-label | Azacitidine, Entinostat, Nivolumab, CC-486 300 |
| NCT03552380 Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | Renal Cell Carcinoma | P2 | Terminated | 12 | Open-label | Entinostat, Nivolumab, Ipilimumab |
| NCT00866333 A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma | Hodgkin's Lymphoma | P2 | Terminated | 49 | Open-label | Entinostat |
| NCT04415073 A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 | Coronavirus, COVID | P2 | Terminated | 1 | RCT, Double-blind | SNDX-6352, Placebo |
| NCT00676663 Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer | Breast Cancer, Estrogen Receptor-Positive Breast Cancer | P2 | Completed | 130 | RCT, Double-blind | entinostat, exemestane, Placebo |
| NCT04301778 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma | P2 | Completed | 5 | Open-label | Durvalumab, SNDX-6352 |
| NCT02922946 Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat | Volunteers, Healthy Volunteers | P1 | Completed | 47 | RCT, Open-label | Entinostat |
| NCT03924245 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | P1 | Terminated | 3 | Open-label | Entinostat, Olaparib |
| NCT03192111 A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function | Renal Impairment, Healthy Volunteer | P1 | Completed | 40 | Open-label | Entinostat |
| NCT00754312 A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer | Breast Cancer | P1 | Terminated | 1 | Open-label | SNDX-275 |
| NCT02909452 Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Neoplasms, Neoplasms, Glandular and Epithelial | P1 | Completed | 30 | RCT, Open-label | Entinostat, Pembrolizumab |
| NCT02820961 Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | Breast Cancer, Estrogen Receptor Positive Breast Cancer | P1 | Completed | 61 | Open-label | entinostat, exemestane |
| NCT02922933 A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects | Volunteers, Healthy Volunteers | P1 | Completed | 66 | Open-label | entinostat |
| NCT02897778 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | Neoplasms, Neoplasms, Glandular and Epithelial | P1 | Completed | 30 | RCT, Double-blind | Entinostat, Placebo |
| NCT05406817 Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Acute Leukemia | P1 | Completed | 9 | Open-label | Revumenib |
| NCT07283640 A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | Blinatumomab, Revumenib | P1 | Not Yet Recruiting | 20 | Open-label | Revumenib, Blinatumomab |
| NCT03187015 A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects | Drug Interaction, Healthy Volunteer | P1 | Completed | 26 | Open-label | Entinostat, Midazolam |
| NCT01594398 Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | Lung Cancer, Non Small Cell Lung Cancer (NSCLC) | P1 | Completed | 14 | RCT, Open-label | entinostat, entinostat, Erlotinib, Erlotinib, Exemestane, Exemestane |
| NCT03238027 A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | Solid Tumor, Metastatic Tumor | P1 | Completed | 45 | Open-label | Axatilimab, Durvalumab |
| NCT05326516 A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | P1 | Completed | 30 | Open-label | Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 |
| NCT03473639 A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | Metastatic Breast Cancer, Breast Cancer | P1 | Completed | 13 | Open-label | Entinostat, Capecitabine |
| NCT03760614 A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | Pancreas Cancer | P1 | Withdrawn | — | Open-label | Entinostat, FOLFOX regimen |
| NCT05918913 Expanded Access Program for Revumenib | Relapsed/Refractory Acute Leukemia | NO_LONGER_AVAILABLE | — | — | Revumenib | |
| NCT03361800 Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | Breast Cancer, Invasive Breast Cancer | Early P1 | Terminated | 5 | Open-label | Entinostat |